Navigation Links
Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Date:12/20/2007

SAN DIEGO, Dec. 20 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the initiation of a clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection in patients who have failed the approved standard of care treatments.

The oral, small molecule drug candidate, CTS-1027, is being studied as a treatment for the inflammatory damage to the liver resulting from infection by HCV. CTS-1027 inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. In the liver and in other solid organs, MMPs play an important role in regulating inflammation as well as in maintaining the integrity of the extracellular matrix. CTS-1027 has been shown to be effective in multiple preclinical models of liver disease.

The clinical trial is a double-blind, placebo-controlled, multiple-dose trial lasting for four weeks followed by a voluntary open label period of up to eight additional weeks. The Company expects approximately 100 patients to be enrolled. The clinical trial will be conducted at up to ten medical centers in the U.S. Additional information about the trial can be found at http://www.clinicaltrials.gov (Identifier NCT00570336) or http://clinicaltrials.gov/ct2/show/NCT00570336?term=CTS-1027&rank=1.

"We are excited to initiate this proof of concept trial in HCV patients with CTS-1027," said Steven J. Mento, President and CEO of Conatus. "We believe that CTS-1027 represents a novel approach to treating liver inflammation and look forward to developing this drug candidate to fill an important medical need in HCV-infected patients."

Conatus Pharmaceuticals Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutics to treat
'/>"/>

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... NY (PRWEB) September 11, 2014 Entries are ... Awards—the only awards where peers and colleagues within the healthcare ... Pharma Choice Awards recognize the very best in healthcare creative ... judged by peers in the health and wellness industry. All ... vote for the top campaigns in each category. , ...
(Date:9/11/2014)... 11, 2014 Genera Energy Inc ... and supply chain advancements, recently introduced its newest feedstock ... delivers a consistent biomass product to a customer’s specifications ... lower cost. , “After producing and harvesting a ... to convert a field crop into a uniform format ...
(Date:9/11/2014)... (PRWEB) September 11, 2014 Central Florida ... announce his partnerships with several Brevard County animal hospitals ... Christiansen has been working in the area since January ... animals since 2008, and is happy to now offer ... years Dr. Christiansen has used stem cell therapy with ...
(Date:9/10/2014)... , Schweiz, September 11, 2014 ... Eierstockkrebs, die bei der Jahresversammlung der Europäischen ... bekräftigen die komplette Tumorprofilierung als "Wendepunkt" für ... Caris Registry™ zeigte ein deutlich längeres Überleben ... Eileiter- oder primär peritonealem Krebs, denen Behandlungen ...
Breaking Biology Technology:PM360 Now Accepting Entries for 2014 Pharma Choice Awards 2Genera Energy’s BIN-SPEC™ Reduces Biomass Feedstock Variability 2Genera Energy’s BIN-SPEC™ Reduces Biomass Feedstock Variability 3Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 2Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 3Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 2Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 3Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 4Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 5
... in a series of articles on developing start-up companies ... article focused on the tax law implications of employees ... unemployment insurance. , , Madison, Wis. ... test for determining independent contractor status. Although this test ...
... that a CIO's head has to be on a swivel. ... consistent theme during the Fusion 2007 CEO-CIO Symposium , ... directions, and risk management has surpassed security as the paramount ... opening keynote, where John Swainson, chief executive of CA ...
... web-centric business sector continued its crash in 2001, the directors ... their Wisconsin-based business unit. Their decision was only delayed when ... meeting in New York scheduled for that tragic day. , ... Dan Maynard pleaded with board members to keep the division ...
Cached Biology Technology:Early Stage, Step 8: Misclassifying workers brings risk 2Early Stage, Step 8: Misclassifying workers brings risk 3Early Stage, Step 8: Misclassifying workers brings risk 4Early Stage, Step 8: Misclassifying workers brings risk 5Fusion 2007: IT threats make risk management paramount 2Fusion 2007: IT threats make risk management paramount 3Connecture's Maynard finds IT business opportunity in adversity 2Connecture's Maynard finds IT business opportunity in adversity 3Connecture's Maynard finds IT business opportunity in adversity 4Connecture's Maynard finds IT business opportunity in adversity 5Connecture's Maynard finds IT business opportunity in adversity 6
(Date:9/11/2014)... are more than 300,000 cases of Lyme disease in the ... to the CDC were concentrated heavily in the Northeast and ... In fact, the disease gets its name from the northeastern ... However, a new article published in the Journal of ... disease Ixodes scapularis , also known as blacklegged ...
(Date:9/11/2014)... known for her work as a high-energy experimental particle ... international consortium of scientists who detected the Higgs boson ... Hadron Collider. , But Bean, a professor of physics ... a long-running passion for engaging the public with science. ... artists and museum educators in the creation of "Quarked," ...
(Date:9/11/2014)... A new study led by the Wildlife Conservation ... where leopards prowl at night, it,s not livestock that,s ... friend. , The study, which looked at scat samples ... that 87 percent of their diet was made up ... most common prey item at 39 percent and domestic ...
Breaking Biology News(10 mins):Physics researcher to advise faith-based office in US Department of State 2Study: Cat bites dog 2
... men die of prostate cancer. It,s Australia,s second worst ... cancer on women. Current therapies for prostate ... the tumour or cutting off the supply of the ... impotence. Growing cells need an essential nutrient, the ...
... of the scientific and technical publishing business of John Wiley ... Society Located in Taipei have signed an agreement to closely ... Chemical Society . The journal will be available online from ... most extensive multidisciplinary collections of online resources, used by 10 ...
... distinct from hematopoietic cells, are an essential component ... for the long-term maintenance of hematopoietic stem cells ... stromal cells regulate the proliferation and differentiation of ... factors and extracellular matrix, and through physical cell-cell ...
Cached Biology News:Starving prostate cancer 2Journal of the Chinese Chemical Society expands international reach with Wiley-VCH 23-D long-term bone marrow culture to analyze stromal cell biological function 2
...
...
... derived from the Spodoptera frugiperda Sf21 cell line ... transfections, plaque assays, virus production, and protein expression. ... optimizes recovery of viable cells after thawing. They ... Cell Medium and can also be grown in ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: